Nuclear Receptor Resource
  • Home
  • Nuclear Receptors
  • Education
    • General Information
    • Drawings
    • White Papers
    • New Publications
    • Other Resources
    • Newsletter Archive
  • About
    • About NRR
    • About the Editor
    • Sponsor
  • Contact
    • Contact NRR
Select Page

GPR40 partial agonist MK-2305 lower fasting glucose in the Goto Kakizaki rat via suppression of endogenous glucose production

by Marketing | May 23, 2017 | New Publications

ABSTRACT GPR40 (FFA1) is a fatty acid receptor whose activation results in potent glucose lowering and insulinotropic effects in vivo. Several reports illustrate that GPR40 agonists exert glucose lowering in diabetic humans. To assess the mechanisms by which GPR40...

Structural basis for differential activities of enantiomeric PPARγ agonists: Binding of S35 to the alternative site

by Marketing | Apr 4, 2017 | New Publications

ABSTRACT Peroxisome proliferator-activated receptor γ (PPARγ) is a member of the nuclear receptor superfamily. It functions as a ligand-activated transcription factor and plays important roles in the regulation of adipocyte differentiation, type 2 diabetes mellitus,...

Pyrintegrin Induces Soft Tissue Formation by Transplanted or Endogenous Cells

by Marketing | Jan 27, 2017 | New Publications

ABSTRACT Focal adipose deficiency, such as lipoatrophy, lumpectomy or facial trauma, is a formidable challenge in reconstructive medicine, and yet scarcely investigated in experimental studies. Here, we report that Pyrintegrin (Ptn), a 2,4-disubstituted pyrimidine...

Lesinurad, a novel, oral compound for gout, acts to decrease serum uric acid through inhibition of urate transporters in the kidney

by Marketing | Oct 3, 2016 | New Publications

ABSTRACT Background Excess body burden of uric acid promotes gout. Diminished renal clearance of uric acid causes hyperuricemia in most patients with gout, and the renal urate transporter (URAT)1 is important for regulation of serum uric acid (sUA) levels. The URAT1...

Leoligin, the major lignan from edelweiss, inhibits 3-hydroxy-3-methyl-glutaryl-CoA reductase and reduces cholesterol levels in ApoE −/− mice

by Marketing | Aug 2, 2016 | New Publications

ABSTRACT The health benefit through the control of lipid levels in hyperlipidaemic individuals is evident from a large number of studies. The pharmacological options to achieve this goal shall be as specific and personalized as the reasons for and co-factors of...
« Older Entries

Sponsored By

Indigo_Logo_4color INDIGO Biosciences, industry-leading provider of both products and services focused on nuclear receptors.

Join the Mailing List

Sign up to join INDIGO Biosciences mailing list.

Sign Up!

About this site

This website utilizes a wide variety of external resources and databases. This optimizes the simplicity in keeping up-to-date, but it decreases the amount that is "personalized" by the editors of this site, and by you the visitor. Please, take time to add to the weblog or to contact the NRR. We are always looking for contributions, suggestion and words of encouragement

Editor-in-Chief

Jack Vanden Heuvel, PhD
Professor of Molecular Toxicology
Penn State University
Disclaimer: Dr. Vanden Heuvel is CSO of INDIGO Biosciences Inc. and is compensated for his activity.
NRR Nuclear Receptor Resource


© 2016 Nuclear Receptor Resource.
All Rights Reserved